What is the main business of Archigenes Pharma?

The main business activity of Archigenes Pharma focuses on manufacture of basic pharmaceutical products.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on January 31, 2019.

Where is the headquarters located?

The headquarters is located at: ul. Nad Strumykiem 21, 05-500 Józefosław.

What is the share capital?

The share capital of the company is PLN 5,000 (approx. $1,351).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.

What revenue was generated?

In 2025, the company generated total revenue of $7,280, representing a decrease of 53.2% compared to 2024.

Is the company profitable?

No, in 2025 the company was not profitable, reporting a net loss of $13,281. For comparison, in 2024 the loss was $18,502, meaning the company reduced its loss by 28.4%.

What is the main operating cost?

The largest operating cost category falls under other operating costs. This category amounted to $14,568 in 2025, representing 71% of all operating expenses.

Archigenes Pharmasp. z o.o.

Manufacture of basic pharmaceutical products

KRS: NIP: REGON:

Overview

Status

Suspended

Registry date

2019-01-31

Share capital

5,000.00 PLN

Registered address

ul. Kineskopowa 1/114, 05-500 Piaseczno, Poland

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 45 days early.

202531/03/2026
202417/03/2025
202318/06/2024
202214/07/2023
202130/06/2022
202015/10/2021

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 7.28kMedianUSD 164.14kAverageUSD 2.27m

Net profit

This companyUSD -13.28kMedianUSD 1.03kAverageUSD 108.21k

Operating costs

This companyUSD 20.56kMedianUSD 187.05kAverageUSD 2.07m

Assets

This companyUSD 24.58kMedianUSD 115.76kAverageUSD 1.52m

Industry

Trademarks

Archigenes Pharma holds 7 active trademarks registered with the Polish Patent Office. The first mark was filed in 2020.

Mark	Number	Classes	Status	Protected until
ITERUM(word)	Z.517551	3, 5	Protected	Aug 27, 2030
NILREST(word)	Z.516351	5	Protected	Jul 23, 2030
CRASSDERM(word)	Z.516350	5	Protected	Jul 23, 2030
AHG	Z.510231	3, 5, 10, 35	Protected	Feb 14, 2030
ARCHIGENES PHARMA	Z.510224	3, 5, 10, 35	Protected	Feb 14, 2030

Mark	Protected until
ITERUM(word)	Aug 27, 2030
NILREST(word)	Jul 23, 2030
CRASSDERM(word)	Jul 23, 2030
AHG	Feb 14, 2030
ARCHIGENES PHARMA	Feb 14, 2030

Authorized Representatives

Ewa Swacha – President of the Management Board

Manner of representation

In the case of a one-person management board – the President of the Management Board independently; in the case of a multi-member management board – two members of the management board jointly, or one member of the management board jointly with a commercial proxy.

Ownership

Owner	Shares	Share value	Stake
Ewa Swachaage 54	99	$1,337.12	99%
Others	1	$13.51	1%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2020-02-01.

Nest Bank
71 2530 0008 2068 1065 2049 0001

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
Natur DayS.A.	$680,635.59	naturday.pl
Biotriosp. z o.o.	$453,662.22	biotrio.pl
Nature's Voicesp. z o.o.	$181,977.76	naturesvoice.eu
Pexon Polandsp. z o.o.	$122,615.96	pexon.pl
Munar PharmaS.A.	$85,649.72	munar.pl
Bioresearch PharmaS.A.	$21,432.15	bioresearchpharma.com
Sanford Biotechsp. z o.o.	$2,586.64	sanfordbiotech.com
Cefeasp. z o.o.	$294.66	cefea.pl
Auxilius PharmaS.A.	$0.83	auxiliuspharma.com
Grupa FinepharmS.A.	–	finepharm.pl

Change history

Date	Event
2026-05-01	Business suspended
2019-01-31	Entered in the register

FAQ

Last updated: 2026-09-24